Please assess the completion status of the following clinical trial:

Trial Title: Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of non-Hodgkin's lymphoma~* Disease exclusively localised into the CNS at first diagnosis and failure~* Progressive or recurrent disease~* Previous treatment with HDMTX containing CHT and/or RT~* Presence of at least one target lesion, bidimensionally measurable~* Age 18 - 75 years~* ECOG performance status \< 3 (Appendix 1).~* No known HIV disease or immunodeficiency~* HBsAg-negative and Ab anti-HCV-negative patients.~* Adequate bone marrow function (plt \> 100000 mm3, Hb \> 9 g/dl, ANC \> 2.000 mm3)~* Adequate renal function (serum creatinine \< 2 times UNL)~* Adequate hepatic function (SGOT/SGPT \< 3 times UNL, bilirubin and alkaline phosphatase \< 2 times UNL)~* Adequate cardiac function (VEF ≥ 50%)~* Absence of any psycological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential.~* No previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease since at least 5 years.~* No concurrent treatment with other experimental drugs.~* Informed consent signed by the patient before registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).